Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegetron Duration (24 vs 48 Weeks) in Genotype 1 HCV
NCT00423800Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2006
- Primary completion
- Oct 2009
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
01
Overview
A Phase 3 trial of peginterferon alfa-2b, ribavirin in hepatitis C (HCV), sponsored by Merck & Co.. Started Dec 2006; status: terminated.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00423800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00423800.